{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:38:00Z","timestamp":1791909480940,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date have been limited by small sample sizes and neglecting to include non-North American and European populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a global, cross-sectional online survey of adults (n = 5,268, 47.2% women) self-reporting past or current psychedelic use and investigated whether psychedelic use was associated with changes in use of other substances.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nearly three-quarters (70.9%; n = 3,737\/5,268) reported ceasing or decreasing use of one or more non-psychedelic substances after naturalistic psychedelic use. Among those with previous use, 60.6% (n = 2,634\/4,344) decreased alcohol use, 55.7% (n = 1,223\/2,197) decreased antidepressant use, and 54.2% (n = 767\/1,415) decreased use of cocaine\/crack. Over a quarter of the sample indicated that their decrease in substance use persisted for 26 weeks or more following use of a psychedelic. Factors associated with decreased use included a motivation to either decrease one\u2019s substance use or self-treat a medical condition. Importantly, 19.8% of respondents also reported increased or initiated use of one or more other substances after psychedelic use, with illicit opioids (14.7%; n = 86\/584) and cannabis (13.3%; n = 540\/4,064) having the highest proportions. Factors associated with increased substance use included having a higher income and residing in Canada or the US.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Although limited by cross-sectional study design, this large observational study will help inform future studies aiming to investigate the relationship between substance use patterns and psychedelic use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2024.1349565","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T05:51:48Z","timestamp":1708581108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey"],"prefix":"10.3389","volume":"15","author":[{"given":"Nicolas G.","family":"Glynos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Aday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Boehnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long\u2013term effects of psychedelic drugs: A systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","article-title":"Psychedelic therapy for depressive symptoms: A systematic review and meta\u2013analysis","volume":"322","author":"Ko","year":"2023","journal-title":"J Affect Disord"},{"key":"B3","doi-asserted-by":"publisher","first-page":"120097","DOI":"10.1016\/j.neuroimage.2023.120097","article-title":"Classical and non\u2013classical psychedelic drugs induce common network changes in human cortex","volume":"273","author":"Dai","year":"2023","journal-title":"Neuroimage"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530","article-title":"Single\u2013dose psilocybin treatment for major depressive disorder","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single\u2013dose psilocybin for a treatment\u2013resistant episode of major depression: Impact on patient\u2013reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J Affect Disord"},{"key":"B6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin\u2013assisted therapy on major depressive disorder","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life\u2013threatening illness A randomized, double\u2013blind, placebo\u2013controlled Phase II study","volume":"93","author":"Holze","year":"2022","journal-title":"Biol Psychiat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA\u2013assisted therapy for moderate to severe PTSD: a randomized, placebo\u2013controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long\u2013term follow\u2013up of psilocybin\u2013facilitated smoking cessation","volume":"43","author":"Johnson","year":"2016","journal-title":"Am J Drug Alcohol Abus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin\u2013assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiat"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221101061","article-title":"Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample","volume":"36","author":"Nygart","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.831092","article-title":"Effects of naturalistic psychedelic use on depression, anxiety, and well\u2013being: associations with patterns of use, reported harms, and transformative mental states","volume":"13","author":"Raison","year":"2022","journal-title":"Front Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/psymed.2023.0030","article-title":"Psychedelic use among psychiatric medication prescribers: effects on well\u2013being, depression, anxiety, and associations with patterns of use, reported harms, and transformative mental states","volume":"1","author":"Herrmann","year":"2023","journal-title":"Psychedelic Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1199642","article-title":"Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey","volume":"14","author":"Nayak","year":"2023","journal-title":"Front Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"agad078","DOI":"10.1093\/alcalc\/agad078","article-title":"Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: a retrospective survey","volume":"59","author":"Kervadec","year":"2023","journal-title":"Alcohol Alcohol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve\u2013month follow\u2013up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"Am J Drug Alcohol Abus"},{"key":"B17","doi-asserted-by":"publisher","first-page":"45331","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment\u2013refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-06046-9","article-title":"Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study","volume":"239","author":"van Oorsouw","year":"2022","journal-title":"Psychopharmacology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.883869","article-title":"Decreases in state and trait anxiety post\u2013psilocybin: A naturalistic, observational study among retreat attendees","volume":"13","author":"Kiraga","year":"2022","journal-title":"Front Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"108071","DOI":"10.1016\/j.drugalcdep.2020.108071","article-title":"Trends in LSD use among US adults: 2015\u20132018","volume":"212","author":"Yockey","year":"2020","journal-title":"Drug Alcohol Depen"},{"key":"B21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelic drug legislative reform and legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiat"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101675","DOI":"10.1016\/j.eclinm.2022.101675","article-title":"Quantifying the global burden of mental disorders and their economic value","volume":"54","author":"Arias","year":"2022","journal-title":"eClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31612-X","article-title":"The Lancet Commission on global mental health and sustainable development","volume":"392","author":"Patel","year":"2018","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/shm\/hkl039","article-title":"\u2018Hitting Highs at Rock Bottom\u2019: LSD Treatment for Alcoholism, 1950\u20131970","volume":"19","author":"Dyck","year":"2006","journal-title":"Soc Hist Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta\u2013analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5\u2013HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J Psychopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia\u2013Romeu","year":"2019","journal-title":"J Psychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey","volume":"10","author":"Garcia\u2013Romeu","year":"2020","journal-title":"Front Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/dar.13348","article-title":"Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international cross\u2013sectional survey","volume":"41","author":"Perkins","year":"2022","journal-title":"Drug Alcohol Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"103518","DOI":"10.1016\/j.drugpo.2021.103518","article-title":"Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting","volume":"100","author":"Argento","year":"2022","journal-title":"Int J Drug Policy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use disorder in a nationally\u2013representative U.S. adult sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10578","DOI":"10.1038\/s41598-022-14809-3","article-title":"Associations between classic psychedelics and nicotine dependence in a nationally representative sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/02791072.2022.2108356","article-title":"Naturalistic psychedelic use: A world apart from clinical care","volume":"55","author":"Glynos","year":"2023","journal-title":"J Psychoact Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11469-023-01085-z","article-title":"Changed substance use after psychedelic experiences among individuals in Canada","author":"Boehnke","year":"2023","journal-title":"Int J Ment Health Addict"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2050324519872284","DOI":"10.1177\/2050324519872284","article-title":"2018: A watershed year for psychedelic science","volume":"5","author":"Aday","year":"2019","journal-title":"Drug Sci Polic Law"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: A prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11469-014-9510-5","article-title":"Treatment motivation predicts substance use treatment retention across individuals with and without co\u2013occurring mental illness","volume":"12","author":"Shields","year":"2014","journal-title":"Int J Ment Heal Addict"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/0193841X0102500202","article-title":"A review of temporal effects and outcome predictors in substance abuse treatment studies with long\u2013term follow\u2013ups","volume":"25","author":"McKay","year":"2001","journal-title":"Eval Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1300\/J029v16n03_06","article-title":"The impact of motivation to change on substance use among adolescents in treatment","volume":"16","author":"Breda","year":"2007","journal-title":"J Child Adolesc Subst Abus"},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.2021.2022817","article-title":"Knowledge, perceptions, and use of psychedelics among individuals with fibromyalgia","volume":"55","author":"Glynos","year":"2023","journal-title":"J Psychoact Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 Accounts of increased \u201cConnectedness\u201d and \u201cAcceptance\u201d After psilocybin for treatment\u2013resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J Humanist Psychol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/17439760.2018.1484940","article-title":"The development of the Awe Experience Scale (AWE\u2013S): A multifactorial measure for a complex emotion","volume":"14","author":"Yaden","year":"2019","journal-title":"J Posit Psychol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.623985","article-title":"Psychedelic communitas: intersubjective experience during psychedelic group sessions predicts enduring changes in psychological wellbeing and social connectedness","volume":"12","author":"Kettner","year":"2021","journal-title":"Front Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12985","article-title":"Exploring ayahuasca\u2013assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada","volume":"38","author":"Argento","year":"2019","journal-title":"Drug Alcohol Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca\u2013assisted therapy for addiction: results from a preliminary observational study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr Drug Abus Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06187-5","article-title":"The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world","volume":"239","author":"Watts","year":"2022","journal-title":"Psychopharmacology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.663447","article-title":"The strengths and barriers recovery scale (SABRS): relationships matter in building strengths and overcoming barriers","volume":"12","author":"Best","year":"2021","journal-title":"Front Psychol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.964671","article-title":"Editorial: human connection as a treatment for addiction","volume":"13","author":"Clements","year":"2022","journal-title":"Front Psychol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1178221819833379","DOI":"10.1177\/1178221819833379","article-title":"How social relationships influence substance use disorder recovery: A collaborative narrative study","volume":"13","author":"Pettersen","year":"2019","journal-title":"Subst Abus: Res Treat"},{"key":"B51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1057\/s41599-021-00710-3","article-title":"The effects of social isolation on well\u2013being and life satisfaction during pandemic","volume":"8","author":"Clair","year":"2021","journal-title":"Humanit Soc Sci Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41398-022-02178-4","article-title":"The effects of social isolation stress and discrimination on mental health","volume":"12","author":"Brandt","year":"2022","journal-title":"Transl Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"key":"B54","doi-asserted-by":"publisher","first-page":"109220","DOI":"10.1016\/j.neuropharm.2022.109220","article-title":"Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling","volume":"218","author":"Henningfield","year":"2022","journal-title":"Neuropharmacology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2023.2242353","article-title":"The relationship between naturalistic psychedelic use and clinical care in Canada","author":"Glynos","year":"2023","journal-title":"J Psychoact Drugs"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0549","article-title":"Emerging challenges for psychedelic therapy","volume":"80","author":"Aday","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e221618","DOI":"10.1001\/jamahealthforum.2022.1618","article-title":"Applying lessons from cannabis to the psychedelic highway","volume":"3","author":"Boehnke","year":"2022","journal-title":"JAMA Heal Forum"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1349565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T05:51:58Z","timestamp":1708581118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1349565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":59,"alternative-id":["10.3389\/fpsyt.2024.1349565"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1349565","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]},"article-number":"1349565"}}